ATAI Life Sciences N.V. Proxy Statement Filed
Ticker: ATAI · Form: DEFA14A · Filed: Jul 2, 2025 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | DEFA14A |
| Filed Date | Jul 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, governance
TL;DR
ATAI Life Sciences proxy statement filed, no fee, shareholder vote coming.
AI Summary
ATAI Life Sciences N.V. filed a Definitive Proxy Statement (DEFA14A) on July 2, 2025, related to soliciting materials under Rule 14a-12. The filing indicates no fee was required for this submission. Christian Angermayer is mentioned in the filing.
Why It Matters
This filing is a proxy statement, which means shareholders will be asked to vote on certain matters, potentially impacting the company's governance and future direction.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (proxy statement) and does not inherently indicate new risks.
Key Numbers
- 20250702 — Filing Date (Date the DEFA14A was filed)
- 20250701 — Date as of Change (Date of change in filing information)
Key Players & Entities
- ATAI Life Sciences N.V. (company) — Registrant
- Christian Angermayer (person) — Mentioned in filing
- 0001140361-25-024438 (filing_id) — Accession Number
FAQ
What type of SEC filing is this?
This is a DEFA14A, a Definitive Proxy Statement.
Who is the registrant?
The registrant is ATAI Life Sciences N.V.
When was this filing made?
The filing was made on July 2, 2025.
Is there a filing fee associated with this document?
No fee is required for this filing.
What rule does this filing fall under for soliciting material?
This filing is soliciting material under Rule 14a-12.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on July 2, 2025 by Christian Angermayer regarding ATAI Life Sciences N.V. (ATAI).